Tivozanib is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptors (VEGFRs) to inhibit tumor angiogenesis, thereby slowing the growth and spread of cancer cells. Its application is particularly significant for patients who have previously undergone systemic treatments, offering a targeted therapy option with a favorable safety profile. Tivozanib is administered orally, making it a convenient option for patients requiring long-term management of the disease. Clinical trials have demonstrated its efficacy in improving progression-free survival, making it a valuable addition to the therapeutic arsenal against advanced RCC.